Exact Sciences (NASDAQ: EXAS) reported Q4 EPS of ($0.18), $0.06 better than the analyst estimate of ($0.24). Revenue for the quarter came in at $87.4 million versus the consensus estimate of $85.74 million.

GUIDANCE:

Exact Sciences sees FY2018 revenue of $420-430 million, versus the consensus of $422.13 million.

• completed Cologuard test volume of 900,000-920,000 tests during 2018.

For earnings history and earnings-related data on Exact Sciences (EXAS) click here.